An Observational Study of Herceptin SC Safety in Breast Cancer

CompletedOBSERVATIONAL
Enrollment

600

Participants

Timeline

Start Date

June 26, 2015

Primary Completion Date

January 31, 2020

Study Completion Date

January 31, 2020

Conditions
Breast Cancer
Trial Locations (23)

10475

Myongji Hospital, Gyeonggi-do

14068

Hallym University Sacred Heart Hospital, Gyeonggi-do

16499

Ajou University Medical Center, Gyeonggi-do

21565

Gachon University Gil Medical Center, Incheon

22332

Inha University Hospital, Incheon

41931

Keimyung University Dongsan Medical Center, Daegu

44033

Ulsan University Hosiptal, Ulsan

49241

Pusan National University Hospital, Busan

49267

Kosin University Gospel Hospital, Busan

50612

Pusan National University Yangsan Hospital, Gyeongsangnam-do

52727

Gyeongsang National University Hospital, Gyeongsangnam-do

54538

Wonkwang University School of Medicine & Hospital, Jeonlabuk-do

58128

Chonnam National University Hwasun Hospital, Jeollanam-do

(0)6351

Samsung Medical Center, Seoul

01757

Inje University, Sanggye-Paik Hospital, Seoul

01812

Korea Cancer Hospital of Korea Institute of Radiological and Medical Sciences, Seoul

03722

Severance Hospital, Yonsei University Health System, Seoul

04619

Cheil General Hospital & Women's Healthcare Center, Seoul

06273

Gangnam Severance Hospital, Seoul

06973

ChungAng University Hospital, Seoul

07061

Borame Medical Center, Seoul

07985

Ewha Womans University Mokdong Hospital, Seoul

Unknown

Miz Medi Hospital, Seoul

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02305628 - An Observational Study of Herceptin SC Safety in Breast Cancer | Biotech Hunter | Biotech Hunter